• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AC Immune SA - Common Stock (NQ:ACIU)

    3.040 +0.100 (+3.40%)
    Streaming Delayed Price Updated: 11:38 AM EST, Dec 18, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about AC Immune SA - Common Stock

    < Previous 1 2 Next >
    News headline image
    AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune to Present at the Jefferies 2025 London Healthcare Conference
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune to Participate in Upcoming Investor Conferences
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune to Present at the Jefferies 2024 London Healthcare Conference
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    News headline image
    AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Announces Upcoming Presentations at AD/PD™ 2024
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune to Regain Global Rights to Crenezumab and Semorinemab
    From AC Immune SA
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.